In 2015, Sartwelle and Johnson published a commentary (described as an original article) in this journal on the use of electronic fetal monitoring to prevent cerebral palsy caused by hypoxic-ischemic encephalopathy. 1 This article, one of several on the same theme that have been published in medical and legal journals by one or both of these authors, claims that electronic fetal monitoring is ''junk science'' and should be excluded from the court room based on the Daubert legal principle. [2] [3] [4] As stated in a federal judicial system publication, ''the specific factors explicated by the Daubert Court are (1) whether the expert's technique or theory can be or has been tested-that is, whether the expert's theory can be challenged in some objective sense, or whether it is instead simply a subjective, conclusory approach that cannot reasonably be assessed for reliability; (2) whether the technique or theory has been subject to peer review and publication; (3) the known or potential rate of error of the technique or theory when applied; (4) the existence and maintenance of standards and controls; and (5) whether the technique or theory has been generally accepted in the scientific community.'' 5 Electronic fetal monitoring has been investigated with resultant publications and is widely used in the obstetrics community. Despite this acceptance, are Sartwelle and Johnson correct in their conclusion that electronic fetal monitoring is ''junk science''? The answer is no.
In order to determine whether studies of the use of electronic fetal monitoring in lessening the cerebral palsy rate have reached valid conclusions, an understanding of the epidemiology of cerebral palsy is needed. In order for cerebral palsy to be a consequence of intrapartum asphyxia, the child should manifest a hypoxic-ischemic encephalopathy after birth. This is a form of neonatal encephalopathy. Recent estimates find that neonatal encephalopathy occurs in 3/1000 live births and hypoxic-ischemic encephalopathy occurs in 1.5/1000 live births. The birth prevalence of cerebral palsy is 1-2 per thousand live births, with 10% to 20% being caused by hypoxicischemic encephalopathy. Therefore, cerebral palsy due to hypoxic-ischemic encephalopathy has a prevalence of approximately 1-4 per 10 000 live births. 6 In the 1960s-1970s, the time that electronic fetal monitoring studies were originally done, the belief that a higher percentage of cerebral palsy and intellectual disability was due to brain injury occurring in the intrapartum time period influenced study design.
Animal and human studies showed a correlation between electronic fetal monitoring changes and fetal acidemia. Changes included depression of variability and accelerations and certain changes in fetal heart rate patterns. Sensitivity and positive predictive value were variable. Subsequently, studies were done involving hundreds or thousands of deliveries that usually found no major difference in neonatal mortality and morbidity when comparing the use of electronic fetal monitoring and intermittent auscultation. [7] [8] [9] However, based on the knowledge that cerebral palsy due to hypoxic-ischemic encephalopathy is not common, it can be concluded that these trials were underpowered to detect differences in this major outcome. 9, 10 Furthermore, in most of these studies, hypoxicischemic encephalopathy or later cerebral palsy were not specific outcomes (ie, if one does not ask the right question, one cannot get the needed answer). Rather, outcomes such as neonatal intensive care unit admission, fetal death and neonatal mortality and morbidity, all of which can have different causes besides hypoxic-ischemic encephalopathy, were measured outcomes. The duration and type of fetal heart rate abnormalities were not common study variables, even though certain heart rate patterns, such as absent variability and recurrent late decelerations, recurrent variable decelerations, or bradycardia, have a stronger association with an adverse outcome and are classified as category III tracings. 6 Therefore, it is not surprising that a consistent relationship between electronic fetal monitoring abnormalities and the occurrence of hypoxic-ischemic encephalopathy and later cerebral palsy was difficult to establish.
There have been efforts to improve the reliability of electronic fetal monitoring interpretation and communication of electronic fetal monitoring abnormalities in a timely fashion to prevent their evolution into more ominous patterns. Recent studies have shown that neonatal outcomes improve when caregiver education programs are implemented and specific monitoring practices are utilized. In the United Kingdom, obstetrics emergencies training courses resulted in a significant reduction in abnormal 5-minute Apgar scores and hypoxic-ischemic encephalopathy. Fetal monitoring practices in Texas that included regulation of oxytocin infusion by the presence or absence of specific category II electronic fetal monitoring tracings led to a reduction in the NICU admission rate and cesarean section delivery rate. In Australia, a labor and delivery staff education program reduced the hypoxic-ischemic encephalopathy rate, with the study model suggesting a drop from 250 hypoxic-ischemic encephalopathy events/100 000 live births prior to the program to 160 hypoxic-ischemic encephalopathy events/100 000 live births after program initiation. [11] [12] [13] [14] Electronic fetal monitoring has a biologic basis, supporting research (although most studies are underpowered or have not defined appropriate study variables or outcomes), and evidence that, when utilized as part of an ongoing quality improvement program, results in improved neonatal outcome. Looking beyond Sartwelle and Johnson's verbal diatribes, name calling, and undisclosed conflicts of interest (one being a malpractice defense lawyer and the other running a business called Legal Medicine Consultants), it is obvious that electronic fetal monitoring does not meet their ''junk science'' classification based on the Daubert legal principle. Rather, as has been stated (and inappropriately disparaged by Sartwelle and Johnson), more research is needed to define the use of electronic fetal monitoring in appropriate target populations, in determination of neonatal outcome, in utilization with other measures of fetal functioning, and in quality improvement and education programs.
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